<DOC>
	<DOCNO>NCT02336646</DOCNO>
	<brief_summary>Bone marrow MSCs isolate allogenic donor , expand hypoxic condition use medium contain serum animal-derived reagent , applies Phase Ⅰ/Ⅱ study treat 18 recipient ischemic limb disease .</brief_summary>
	<brief_title>Cell Therapy With Mesenchymal Stem Cell Ischemic Limb Disease</brief_title>
	<detailed_description>Ischemic limb disease remain one major cause morbidity mortality industrialize world despite development several new therapeutic modality . Based experimental data demonstrate infusion injection stem/progenitor cell enhance blood flow model cardiovascular disease , clinical trial initiate 2001 treat patient critical limb ischemia cardiac ischemia circulate blood bone marrow-derived cell . Despite promise , pending uncertainty practical limitation attenuate therapeutic use stem/progenitor cell ischemic limb disease . The main theme method current program project , base expertise , track record , preliminary result PI 's laboratory , focus clinical study use allogenic mesenchymal stem cell ( MSCs ) , expand hypoxic condition ( 1 % O2 ) , treat ischemic limb . This project integrate coordinated effort aim overcome regulation cell product , barrier preclinical clinical study . For purpose , specially set core laboratory stem/progenitor cell production quality control Cell Therapy Clean Room 9th floor Medical Science Technology Building Taipei Veterans General Hospital . We also complete preclinical study use allogenic hypoxic mouse MSCs treat limb ischemia . In current project , bone marrow MSCs isolate allogenic donor , expand hypoxic condition use medium contain serum animal-derived reagent , applies Phase Ⅰ/Ⅱ study treat 18 recipient ischemic limb disease three year .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Fontaine stage &gt; II , total walk distance &lt; 100 , stair &lt; 1 floor , ulcer / necrosis Established critical limb ischemia , clinically hemodynamically confirm per Rutherford Ⅱ4 , Ⅲ5 , Ⅲ6 ; Patients Infrainguinal arterial occlusive disease rest pain ischemic ulcer/necrosis , eligible fail traditional revascularization treatment Ankle Brachial Pressure Index ( ABPI ) ≤ 0.6，ankle pressure ≤ 70 mm Hg , TcPO2 ≤ 60 mmHg foot No response medication ( aspirin cilostazol ) Normal liver renal function On regular medication hypertension The mentioned patient combine infection systemic septicemia . ( ps , patient poor control diabetes , hypertension hyperlipidemia also exclude Patient Immunocompromised immunosuppressed Type I Diabetes Patients stroke myocardial infarction within last 3 month Hb % &lt; 10 gm % , Serum Creatinine ≥ 2mg % , Serum Total Bilirubin ≥2mg % , HbA1c &gt; 8 %</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>